NewGenIvf Group Limited filed a Form 6-K with the U.S. Securities and Exchange Commission on November 20, 2026, disclosing the closing of an underwritten public offering and a related senior convertible note repurchase agreement.

Key Highlights

  • Offering closed November 20, 2026: The company issued 9,501,148 Class A ordinary shares and pre-funded warrants to purchase up to 61,927,422 Class A ordinary shares, representing an aggregate of 71,428,570 shares issued or underlying the Pre-Funded Warrants.
  • Offering price: $0.035 per Class A ordinary share and $0.03499 per Pre-Funded Warrant, with a Pre-Funded Warrant exercise price of $0.00001 per share.
  • Gross proceeds: Approximately $2.5 million, before deducting underwriting discounts, commissions, and offering expenses.
  • Underwriting discount: Aegis Capital Corp., acting as sole book-running manager, is to receive a discount equal to 9.0% of gross proceeds, plus expense reimbursement of up to $80,000.
  • Note repurchase: The company applied approximately $625,000 of gross proceeds to repurchase $584,112 in principal of its outstanding Exchange Note, reducing the principal balance from $5,769,469 to $5,185,357.
  • Lock-up agreements: Officers and directors entered into 60-day lock-up agreements following the closing, subject to customary exceptions.

NewGenIvf Group Closes Underwritten Offering and Restructures Senior Note

According to the filing, NewGenIvf Group Limited (NASDAQ:NIVF) entered into an underwriting agreement with Aegis Capital Corp. on November 19, 2026, and closed the offering on November 20, 2026. The offering was made on a firm commitment basis under an effective shelf registration statement on Form F-3 (No. 333-299649), declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus were filed with the SEC on November 20, 2026.

The company disclosed that of the 9,501,148 Class A ordinary shares issued at closing, 8,350,578 were issued upon the pre-closing exercise of pre-funded warrants. The filing states that the company's management "will retain broad discretion to apply these net proceeds," which the company expects to direct toward commercialization and expansion of the Nodexus advanced cytometry technology and its assisted reproductive services platform, strategic investments in prediction-market and digital-asset/AI initiatives, real estate interests in the UAE, and general corporate purposes.

Concurrently, the filing discloses a Limited Waiver and Repurchase Agreement entered into on November 19, 2026, with the holder of the company's Exchange Note originally issued under an Amendment and Exchange Agreement dated August 11, 2026. Under the Waiver Agreement, the holder agreed to a one-time limited waiver modifying clause (y) of Section 32(g) of the Exchange Note during the Waiver Period, setting it at "76% of the lowest daily volume-weighted average price ('VWAP') during the seven consecutive Trading Days ending on and including the Trading Day immediately preceding delivery or deemed delivery of the applicable Conversion Notice." The repurchased $584,112 principal portion of the Exchange Note is automatically cancelled upon completion of the repurchase. The company also agreed to reimburse the holder's counsel $15,000 as a non-accountable Waiver Legal Fee Reimbursement.

What Was Disclosed

NewGenIvf Group Limited reported the closing of a $2.5 million underwritten offering of Class A ordinary shares and pre-funded warrants, an associated partial repurchase of its senior convertible Exchange Note, and lock-up agreements signed by officers and directors.